(415) 353-9888 (appts)
(415) 353-9636 (fax)

Box 1770, UCSF; San Francisco, CA 94143-1770

additional websites:

UCSF Physician Referral Directory

Creighton University, Omaha, NE, B.S., 1969, Medical Technology
University of Nebraska Medical Center, Omaha, NE, M.S., 1974, Clinical Pathology
University of Nebraska Medical Center, Omaha, NE, M.D., 1977, Medicine
University of Nebraska Medical Center, Omaha, NE, Residency, 1980, Internal Medicine
University of Nebraska Medical Center, Omaha, NE, Fellowship, 1983, Oncology

Editorial Boards-Journal of Clinical Oncology 1998-1999, Cancer Research 1995-2000

ASCO/AACR Program Comm. Joint Workshop - "Methods in Clinical Cancer Research", 2000- Course Director

ASCO -- Board of Directors, 1998-2001, President-Elect, 2002-2003. President - 2003- 2004, Past President, 2004 - 2005

NCI/NIH Cancer Centers & Research Prog. Review Comm. - Subcomm. A, 1995-99

NIH Comm., Clinical Onc. Special Emphasis Panel, 1998-1999, Chairperson

NCI Brd of Scientific Counselors, Subcomm. A, July 1999 - June 2004, Member, 2004-2006, Chair.

Engstrom P, Benson AB, Cohen A, Doroshow J, Kiel K, Niederhuber J, Roh M, and Tempero M: NCCN colorectal cancer practice guidelines. Oncology 10:140-175, 1996.

Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Lieberman RP, Sharp JG, Cohen SM, Leichner PK, Augustine SC, Tempero MA, Taylor RJ, and Chiou RK: Radiolabeled iododeoxyuridine: Safety evaluation. J Nucl Med 37:13-16, 1996.

Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, Tempero M, and Colcher D: Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. J Clin Immunol 17:96-106, 1997.

Tempero, MA: Walking a difficult path is easier with a friend: Thoughts from a practicing oncologist. Ann New York Academy of Sciences 809:237-242, 1997.

Tempero MA, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlom J, Wisecarver J, and Colcher D: High dose therapy with 131I labeled monoclonal antibody CC49: A phase I trial. J Clin Oncol, 15:1518-1528, 1997.

Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver JA, and Tempero MA: Patient-specific dosimetry of Indium-111/Yttrium-90-labeled monoclonal antibody CC49. J Nucl Med 38:512-516, 1997.

Habbe TG, McCowan TC, Goertzen TC, LeVeen RF, and Tempero MA: Arterial infusion chemotherapy in the treatment of isolated hepatic colorectal metastases. Semin Interventional Radiology 14:241-53, 1997.

Tempero MA, Abbruzzese J, Benson AB, Cameron JL, Casper ES, Hoffman J, Lawrence T, Martin T, McGinn C, and Willett C:NCCN practice guidelines for pancreatic cancer. NCCN Proceedings, Oncology 11:41-56, 1997.

Habbe TG, McCowan TC, Goertzen TC, LeVeen RF, and Tempero MA: Complications and technical limitations of hepatic arterial infusion catheter placement for chemotherapy. Journal of Vascular and Interventional Radiology 8(1):221, 1997.

Brand R, Capadano M, and Tempero M: A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with non-hematologic malignancies. Invest New Drugs 15:331-341, 1997.

Habbe TG, McCowan TC, Goertzen TC, LeVeen RF, Culp WC, and Tempero MA: Complications and technical limitation of hepatic arterial infusion catheter placement for chemotherapy. Journal of Vascular and Interventional Radiology 9:233-239, 1998.

Tempero M: Pancreatic Cancer. Clin Perspectives in Gastroenterology 1:96-100, 1998.

Brand RE and Tempero MA: Pancreatic cancer. Curr Opin Oncol 10:362-366, 1998.

DiMagno EP, Reber HA, and Tempero MA: AGA Technical Review and Medical Position Statement: Epidemilogy, diagnosis andtreatment of pancreatic ductal adenocarcinoma. Gastroenterology, 117:1463-1484, 1999.

Vose JM, Colcher D, Gobar L, Bierman PJ, Augstine S, Tempero M, Leichner P, Lynch JC, Goldenber D,and Armitage JO: Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leukemia and Lymphoma. 1999.

Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryant K, Fisher DR, Colcher D, Horak ID, and Weiner LM: Phase II trial of yttrium-90-DOTA-BIOTIN targeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clinical Cancer Research6:406-412, 2000.

Gwilt PR, Tempero M, Kremer A, Connolly M, and Ding C: Pharmacokinetics of levamisole in patients treated with 5-Fluorouracil. Cancer Chemother Pharmacol., 45(3):247-51, 2000. PMID: 10663643

Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, and Colcher D: High dose therapy with 90Yttrium labeled monoclonal antibody CC49: A phase I trial. Clin Cancer Res. 6:3095-3102, 2000.

Goel, A, Augustine, S, Baranowska-Kortylewicz, J, Colcher,D, Booth, B, Pavlinkova, G, Tempero, M, and Batra, S. Single-dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single chain Fvs. Clin Cancer Res. 7:175-84, 2001.

Copur MS, Capadano M, Lynch J, Goertzen T, McCowan T, Brand R, Tempero M. Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access. J Clin Oncol, May 1;19(9):2404-12. 2001. PMID: 11331319

Kurizaki, T, Okazaki, S, Sanderson, S, Colcher, D, Enke, C, Tempero, M, Baranowska-Kortylewicz, J. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J of Nuc Med, 43 (7): 957-67, 2002. PMID: 12097469

Kern, S, Hruban, R, Hollingsworth, MA, Brand, R, Adrian, TE, Jaffee, E, Tempero, MA. A white paper: the product of a pancreas cancer think tank. Cancer Res, 2001.

Augustine, S, Norenberg, J, Colcher, D, Vose, J, Gobar, L, Dukat, V, Hohenstein, M, Rutar, F, Jacobson, D, Tempero, M.A. Combination therapy for non-hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice. J of Amer Pharma Association 42:93-100, 2002.

Ko, A, Tempero, M. Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep, 12: 39-45, 2002.

Kurizaki, T, Okazaki, S, Sanderson, S, Colcher, D, Enke, C, Tempero, M, Baranowska-Kortylewicz, J.Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J of Nuc Med, 43 (7): 2002.

Sudan, D, DeRoover, A, Chinnakotla, S, Fox, I, Shaw, B Jr, McCashland, T, Sorrell, M, Tempero, M, Langnas, A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2(8): 774-9, September 2002.

Tempero, M, Plunkett, W, Ruiz van Haperen, V, Hainsworth, J, Hochster, H, Lenzi, R, Abbruzzese, J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. September 15; 21 (18); 3402-8, 2003.

Blackstock, A., Tepper, J, Niedwiecki, D, Hollis, D, Mayer, R, Tempero, MA. Cancer and Leukemia Group B (CALGB) 89805: Phase II Chemorandiation Trial Using Gemcitabine in Patients with Locoregional Adenocarcinoma of the Pancreas. IJGC, vol 34/2, pp 109-118, 2004.

Ko, A.H., Hwang, J., Venook, A.P., Abbruzzese, J., Bergsland, E.K, Tempero, M.A. Serum CA 19-9 response as a surrogate for clinical outcome in patients with advanced pancreatic cancer treated with fixed-dose rate gemcitabine. Brit J Cancer, 93(2):195-9, July 2005.

Tempero M.A., Behrman S., Ben-Josef E., Benson A.B. 3rd, Cameron J.L., Casper E.S., Hoffman J.P., Karl R.C., Kim P., Koh W.J., Kuvshinoff B.W. 2nd, Melvin W.S., Muscarella P. 2nd, Sasson A.R., Shibata S., Shrieve D.C., Talamonti M.S., Tyler D.S., Vickers S.M., Warren R.S., Willett C., Wolff R.A., National Comprehensive Cancer Network. Pancreatic Adenocarcinoma: Clinical Practice Guidelines in Oncology. J NCCN, 3(5):589-626, September 2005.

Ko, A.H., Tempero, M.A. Treatment of metastatic pancreatic cancer. J NCCN, 3(5):627-36, September 2005.

Ko, A.H., Tempero, M.A. Systemic therapy for pancreatic cancer. Semin Radiat Oncol 15(4):245-53, October 2005.

Hruban, R.H., Rustgi, A.K., Brentnall, T.A., Tempero, M.A., Wright, C.V., and Tuveson, D.A. Pancreatic Cancer in Mice and Man: The Penn Workshop 2004. Cancer Res 66:(1): 14-7), January 2006.

Ko, A.H., Dito, E., Schillinger, B., Venook, A.P., Bergsland, E.K., Tempero, M.A. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol, January 2006.

Hruban, R.H., Rustgi, A.K., Brentnall, T.A., Tempero, M.A., Wright, C.V., and Tuveson, D.A. Pancreatic Cancer in Mice and Man: The Penn Workshop 2004. Cancer Res 66(1): 14-7, January, 2006

Jhawer, M, Rosen, L, Dancey, J, Hochster, H, Hamburg, S, Tempero, M.A., Clendeninn, N, Mani, S. Phase II Trial of Nolatrexed Dihydrochloride [Thymitaq, AG 337] in Patients with Advanced Hepatocellular Carcinoma. Invest New Drugs. 25(1):85-94, February, 2007.

Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68 (3):809-16. Epub 2007 Mar 23.PMID: 17363191

Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Apr 1. PMID: 18379729

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb;26 (1):47-52.PMID: 18181045

E. Van Cutsem, M. Dicato, K. Haustermans, N. Arber, J.-F Bosset, D.Cnningham, A. De Gramont, E. Diaz-Rubio, M. Ducreux, R. Goldberg, R. Glynne-Jones, D. Haller, Y.-K. Kang, D. Kerr, R. Labianca, B. D. Minsky, M. Moore, B. Nordlinger, P. Rougier, W. Scheithauer, H.-J. Schmoll, A. Sobrero, J. Tabernero, M.Tempero, C. Van de Velde & J. Zalcberg. The diagnosis and management of rectal cancer:expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007Annals of Oncology 19 (Supplement 6): vi1-vi8, 2008

Wong D, Ko, AH, Hwang, J, Venook, AP, Bergsland, EK, and Tempero, MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving fixed-dose rate gemcitabine. Pancreas 37(3): xx-xx, October 2008.

Ko AH, Tempero MA Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan;136(1):43-5. Epub 2008 Nov 28. PMID: 19041

Kulke MH, Tempero M, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M,.Enzinger PC, Gorsh SM, Goldberg RM, Mayer MJ. A Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination with Cisplatin, Docetaxel, or Irinotecan in Patients with Metastatic Pancreatic Cancer. JCO/2009/221309

Philip, PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol NJ, Emens, L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A;Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus Report of NCI Clinical Trials Planning Meeting on Pancreas Cancer Treatment. JCO/2009/219022 (in press)

7/2/09